Plus Therapeutics Announces Public Offering Aiming to Raise $15 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- Public Offering Pricing: Plus Therapeutics has priced its public offering at $0.38 per unit, aiming to raise approximately $15 million for working capital and general corporate purposes, indicating a pressing need for funding.
- Stock Price Decline: Following the offering announcement, PSTV's stock fell 37.69% to $0.29 in premarket trading on Wednesday, reflecting market concerns about the company's future prospects, with shares trading 47.7% and 48.3% below their 20-day and 50-day simple moving averages, respectively.
- FDA Feedback Integration: Following a Type B meeting with the FDA, Plus Therapeutics plans to incorporate feedback into its trial strategy for leptomeningeal metastases, with a revised protocol expected in 2026, which could significantly impact its competitive position in targeted radiotherapeutics.
- Insurance Agreement Signed: CNSide Diagnostics signed a national agreement with UnitedHealthcare covering over 51 million people, providing a laboratory-developed test for cerebrospinal fluid tumor cell enumeration, enhancing the company's service capabilities in the U.S. market.
Analyst Views on PSTV
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8.00 USD with a low forecast of 2.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.239
Low
2.00
Averages
8.00
High
19.00
Current: 0.239
Low
2.00
Averages
8.00
High
19.00
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
